Pfizer

10 pharmas form nonprofit TransCelerate to accelerate R&D of new medicines

Wednesday, September 19, 2012 02:46 PM

Ten biopharmaceutical companies have formed a non-profit organization, TransCelerate BioPharma, to accelerate the development of new medicines. Participants include Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi.

More... »

Pfizer, Hisun launch joint venture Hisun-Pfizer Pharmaceuticals

Friday, September 14, 2012 11:13 AM

Pfizer, the world's largest research-based pharmaceutical company, and Zhejiang Hisun Pharmaceuticals, a Chinese pharmaceutical company, have launched their joint venture Hisun-Pfizer Pharmaceuticals, to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets.

More... »

Abbott, Astellas collaborate on CMV vaccine trial

Monday, September 10, 2012 11:03 AM

Abbott has signed an agreement to collaborate with Astellas Pharma Global Development in a phase III clinical trial for ASP0113 (TransVax), an investigational vaccine licensed from Vical for preventing cytomegalovirus (CMV) reactivation in transplant patients.

More... »

SFJ, Pfizer collaborate on phase III trial of dacomitinib in lung cancer

Friday, September 7, 2012 11:21 AM

The SFJ Pharmaceuticals Group (SFJ), a global drug development group of companies, has entered into a collaborative development agreement with Pfizer to conduct a phase III clinical trial of Pfizer's investigational pan-HER (pan-human epidermal growth factor receptor) inhibitor, dacomitinib (PF-00299804).

More... »

FDA approves Pfizer’s new orphan drug for chronic myelogenous leukemia

Thursday, September 6, 2012 08:25 AM

The FDA has approved Pfizer’s Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.

More... »

Pfizer, Mylan ink exclusive long-term collaboration for generics in Japan

Thursday, August 23, 2012 02:02 PM

Global research-based pharmaceutical company Pfizer and Canonsburg, Penn.-based pharmaceutical company Mylan have signed a definitive agreement to establish an exclusive long-term strategic collaboration to develop, manufacture, distribute and market generic drugs in Japan.

More... »

Study confirms economic viability of orphan drugs positioned for unmet medical needs

Wednesday, August 22, 2012 12:35 PM

Orphan drugs, developed to treat rare diseases, have the potential to generate as much lifetime revenue as drugs used for more common health conditions, according to a study by Thomson Reuters’ intellectual property and science business.

More... »

Adventrx names Vetticaden as chief medical officer

Monday, August 20, 2012 04:01 PM

Adventrx Pharmaceuticals, a biopharmaceutical company based in San Diego, has appointed Santosh J. Vetticaden, M.D., Ph.D., as chief medical officer and senior vice president.

More... »

AZ, Pfizer enter agreement for OTC Nexium

Wednesday, August 15, 2012 09:41 AM

AstraZeneca, a global biopharmaceutical company, has entered into an agreement with Pfizer, a global research-based pharmaceutical company, for the over-the-counter (OTC) rights for Nexium (esomeprazole magnesium), a prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease (GERD).

More... »

Nodality, Pfizer form multi-year collaboration on autoimmune disease

Thursday, August 9, 2012 02:16 PM

Nodality, a San Francisco-based personalized medicine biotech, has formed a strategic collaboration to provide proprietary single cell network profiling (SCNP) technology as a tool for the development of Pfizer compounds.

More... »